Aurealis Therapeutics Publishes First Study on Four-in-One-Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds

Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the company successfully completed an exclusive license and collaboration agreement with XBiome for the clinical development and commercialization of AUP-16 for Diabetic Foot Ulcer (DFU), other chronic wounds, and inflammatory diseases in Greater China.

“Diabetic ulcers are the leading cause of non-traumatic lower limb amputations, and dramatically increase patient mortality. Despite a huge unmet need, no pharmacological wound healing product has been approved for more than 10 years,” said Thomas Wirth, CSO of Aurealis Therapeutics. “We believe AUP-16 can be a game changer, and we are really happy to have this study published on reputable peer-reviewed journal such as PLOS ONE.”

Dr. Jere Kurkipuro, lead author of the study and Head of Non-Clinical Pharmacology at Aurealis Therapeutics said “Many DFU patients do not respond to standard treatments, and there is a lack of evidence for many of the advanced therapeutic approaches. AUP-16 is designed as a single pharmaceutical entity, based on non-pathogenic bacterium genetically engineered to address all aspects of wound healing. We’re really proud to see that this study shows how the combination of the individual components on the wound microenvironment initiates and improves healing in chronic wounds.”